2 days Why Amgen’s Obesity Drug — And $5 Billion Opportunity — Led To A DowngradeInvestor's Business Daily
Amgen stock dipped Monday after an analyst downgraded shares, saying the opportunity for its weight-loss drug is already baked into the stock.
The post Why Amgen's Obesity Drug — And $5 Billion Opportunity — Led To A Downgrade appeared first on In…